The reiteration of an Outperform rating by a major analyst like RBC Capital suggests a positive sentiment towards Moderna's stock. This could influence investors to share this optimism, potentially driving up the stock price in the short term. The maintenance of the $125 price target indicates that the analyst believes the stock has the potential to reach or exceed this value, which is a positive signal for investors.